Particularly, miR-99a could be a potential therapeutic marker in lung cancer.17 We described two novel miR-99a targets, E2F2 and EMR2, representing two oncogenic proteins that could modulate tumour suppression in NSCLCs. The gene discussed is E2F2; the disease is lung carcinoma.